Evidence map›Paper›PMID 27788210›Full record

ArticlePloS one2016

Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer.

Alina Fedoseienko, Hylke W Wieringa, G Bea A Wisman, Evelien Duiker, Anna K L Reyners, Marten H Hofker, Ate G J van der Zee, Bart van de Sluis, Marcel A T M van Vugt

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Alina FedoseienkoDepartment of Pediatrics, Molecular Genetics Section, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Hylke W WieringaDepartment of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
G Bea A WismanDepartment of Gynecological Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Evelien DuikerDepartment of Pathology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Anna K L ReynersDepartment of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Marten H HofkerDepartment of Pediatrics, Molecular Genetics Section, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Ate G J van der ZeeDepartment of Gynecological Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Bart van de SluisDepartment of Pediatrics, Molecular Genetics Section, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Marcel A T M van VugtDepartment of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
University of Groningen · NLUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Copper metabolism MURR1 domain 1 (COMMD1) protein is a multifunctional protein, and its expression has been correlated with patients' survival in different types of cancer. In vitro studies revealed that COMMD1 plays a role in sensitizing cancer cell lines to cisplatin, however, the mechanism and its role in platinum sensitivity in cancer has yet to be established. We evaluated the role of COMMD1 in cisplatin sensitivity in A2780 ovarian cancer cells and the relation between COMMD1 expression and response to platinum-based therapy in advanced stage high-grade serous ovarian cancer (HGSOC) patients. We found that elevation of nuclear COMMD1 expression sensitized A2780 ovarian cancer cells to cisplatin-mediated cytotoxicity. This was accompanied by a more effective G2/M checkpoint, and decreased protein expression of the DNA repair gene BRCA1, and the apoptosis inhibitor BCL2. Furthermore, COMMD1 expression was immunohistochemically analyzed in two tissue micro-arrays (TMAs), representing a historical cohort and a randomized clinical trial-based cohort of advanced stage HGSOC tumor specimens. Expression of COMMD1 was observed in all ovarian cancer samples, however, specifically nuclear expression of COMMD1 was only observed in a subset of ovarian cancers. In our historical cohort, nuclear COMMD1 expression was associated with an improved response to chemotherapy (OR = 0.167; P = 0.038), although this association could not be confirmed in the second cohort, likely due to sample size. Taken together, these results suggest that nuclear expression of COMMD1 sensitize ovarian cancer to cisplatin, possibly by modulating the G2/M checkpoint and through controlling expression of genes involved in DNA repair and apoptosis.

Indexed as

Adaptor Proteins, Signal TransducingApoptosisCell Line, TumorCell NucleusCisplatinCohort StudiesFemaleG2 Phase Cell Cycle CheckpointsGene Expression Regulation, NeoplasticHumansM Phase Cell Cycle CheckpointsNeoplasm GradingNeoplasm StagingOvarian NeoplasmsAdaptor Proteins, Signal TransducingCisplatinCOMMD1 protein, human

Identifiers

PMID27788210
PMCPMC5082896
OpenAlexW2545829570

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.